Risk Factors for New Detection of Vancomycin-Resistant Enterococci in Acute-Care Hospitals That Employ Strict Infection Control Procedures

Size: px
Start display at page:

Download "Risk Factors for New Detection of Vancomycin-Resistant Enterococci in Acute-Care Hospitals That Employ Strict Infection Control Procedures"

Transcription

1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2003, p Vol. 47, No /03/$ DOI: /AAC Copyright 2003, American Society for Microbiology. All Rights Reserved. Risk Factors for New Detection of Vancomycin-Resistant Enterococci in Acute-Care Hospitals That Employ Strict Infection Control Procedures Alexander A. Padiglione, 1,2 * Rory Wolfe, 2 Elizabeth A. Grabsch, 1 Di Olden, 1 Stephen Pearson, 3 Clare Franklin, 4 Denis Spelman, 4 Barrie Mayall, 3 Paul D. R. Johnson, 1 and M. Lindsay Grayson 1,2 Department of Infectious Diseases, Monash Medical Centre, Clayton, 1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 2 Department of Microbiology, Austin & Repatriation Medical Centre, Heidelberg, 3 and Microbiology Department, Alfred Hospital, Prahran, 4 Victoria, Australia Received 26 August 2002/Returned for modification 13 January 2003/Accepted 7 May 2003 Accurate assessment of the risk factors for colonization with vancomycin-resistant enterococci (VRE) among high-risk patients is often confounded by nosocomial VRE transmission. We undertook a 15-month prospective cohort study of adults admitted to high-risk units (hematology, renal, transplant, and intensive care) in three teaching hospitals that used identical strict infection control and isolation procedures for VRE to minimize nosocomial spread. Rectal swab specimens for culture were regularly obtained, and the results were compared with patient demographic factors and antibiotic exposure data. Compliance with screening was defined as optimal (100% compliance) or acceptable (minor protocol violations were allowed, but a negative rectal swab specimen culture was required within 1 week of becoming colonized with VRE). Colonization with VRE was detected in 1.56% (66 of 4,215) of admissions (0.45% at admission and 0.83% after admission; the acquisition time was uncertain for 0.28%), representing 1.91% of patients. No patients developed infection with VRE. The subsequent rate of new acquisition of VRE was 1.4/1,000 patient days. Renal units had the highest rate (3.23/1,000 patient days; 95% confidence interval [CI], 1.54 to 6.77/1,000 patient days). vanb Enterococcus faecium was the most common species (71%), but other species included vanb Enterococcus faecalis (21%), vana E. faecium (6%), and vana E. faecalis (2%). The majority of isolates were nonclonal by pulsed-field gel electrophoresis analysis. Multivariate analysis of risk factors in patients with an acceptable screening suggested that being managed by a renal unit (hazard ratio [HR] compared to the results for patients managed in an intensive care unit, 4.6; 95% CI, 1.2 to 17.0 [P 0.02]) and recent administration of either ticarcillin-clavulanic acid (HR, 3.6; 95% CI, 1.1 to 11.6 [P 0.03]) or carbapenems (HR, 2.8; 95% CI, 1.0, 8.0 [P 0.05]), but not vancomycin or broad-spectrum cephalosporins, were associated with acquisition of VRE. The relatively low rates of colonization with VRE, the polyclonal nature of most isolates, and the possible association with the use of broad-spectrum antibiotics are consistent with either the endogenous emergence of VRE or the amplification of previously undetectable colonization with VRE among high-risk patients managed under conditions in which the risk of nosocomial acquisition was minimized. In Australian hospitals, unlike those in the United States and Europe, colonization with vancomycin-resistant enterococci (VRE) and disease caused by VRE have only recently become significant nosocomial problems. They have occurred in the presence of a low background rate (0.2%) of fecal colonization with VRE in the general Australian community (25). Clonal outbreaks of VRE (mainly vanb strains) in some acutecare hospitals in 1998 prompted the widespread implementation in many Australian states of guidelines (based on those from the Centers for Disease Control and Prevention) to prevent its spread (4, 17, 20, 28; E. E. Cooper and M. O Reilly, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., p. 643, 1999). Identification of the risk factors associated with * Corresponding author. Mailing address: Infectious Diseases & Clinical Epidemiology Department, Monash Medical Centre, 246 Clayton Rd., Clayton, VIC 3168, Australia. Phone: Fax: alex.padiglione@med.monash.edu.au. Present address: Infectious Diseases and Microbiology Departments, Austin & Repatriation Medical Centre, Studley Rd., Heidelberg, VIC 3084, Australia. colonization with VRE and disease caused by VRE has proved difficult (18). Many studies are potentially confounded by high rates of nosocomial acquisition of VRE, such that differentiation between the factors associated with endogenous emergence, amplification of previously undetectable colonization, or nosocomial spread of VRE has proved difficult. As a result, published rates of colonization with VRE among patients managed in acute-care hospitals appear to vary widely between countries and have variably suggested an association between the acquisition of VRE and recent use of antibiotics, especially vancomycin and/or broad-spectrum cephalosporins (6, 8, 23, 31, 32, 35). However, only a few of these studies have been prospective, and most have had some methodological flaws (19). It is presumed that VRE may become detectable via one of three means: they may emerge in an individual patient as a result of antibiotic selective pressure and gene transfer into otherwise susceptible enterococci, they may be present in small numbers but become amplified to a detectable level under certain conditions, or they are acquired as a result of nosocomial spread. Thus, to more accurately assess the epidemiology 2492

2 VOL. 47, 2003 VRE IN HOSPITALS WITH STRICT INFECTION CONTROL POLICIES 2493 TABLE 1. Predicted time of detectable serum antibiotic levels following dosing in patients with renal impairment a Drug Serum half-life in patients with severe renal failure and undergoing hemodialysis Predicted time after administration of last dose with detectable levels in serum Vancomycin days 7 days Teicoplanin h 7 days Imipenem 3 h Nil Meropenem 20 h 24 h Ceftriaxone h 48 h Cefotaxime 3 11 h 24 h Ceftazidime h 24 h Cefepime 5 13 h 24 h Cefpirome 3 14 h 24 h Metronidazole 7 21 h Nil Ciprofloxacin h 24 h Ticarcillin-clavulanate h Nil Ampicillin 5 20 h 24 h Gentamicin h 48 h Piperacillin-tazobactam 4 6 h Nil a Sources: British National Formulary, Australian Hospital Formulary System, and Bennett (2). of colonization with VRE in settings where nosocomial transmission is less likely, we elected to investigate the rate of colonization with VRE among high-risk patients in acute-care hospitals which used strict infection control and isolation procedures. MATERIALS AND METHODS Study sites and patient eligibility. The study was performed in 11 high-risk units in three university teaching hospitals in Melbourne, Victoria, Australia (Alfred Hospital [AH], Austin and Repatriation Medical Centre [ARMC], and Monash Medical Centre [MMC]), during a 15-month period commencing in April Study units included the renal units (n 3) and the intensive care units (ICUs; n 5) at all three institutions (at AH this involved three ICUs, the general, road trauma, and cardiothoracic ICUs) as well as two transplant units (at AH, the heart-lung transplant unit; at ARMC, the liver transplant unit) and one hematology-oncology unit (MMC). The three hospitals were selected because they used identical infection control measures based on the guidelines of the Centers for Disease Control and Prevention. These included strict isolation measures for patients colonized with VRE to prevent cross-infection and screening for colonization among contacts with identified cases (4, 20). Patients were eligible for participation in the study if they were aged 15 years and had been admitted to a study unit for more than 24 h. Basic demographic and health data were recorded, including age; sex; managing unit; and the presence of diabetes mellitus, immunosuppression (use of prednisolone, cyclosporine, azathioprine, mycophenolate, tacrolimus, or anticancer chemotherapy), transplantation, renal failure (serum creatinine level, 0.25 mmol/liter), or hepatic failure (clinical diagnoses were made by the treating physician). In addition, we gathered data regarding previous hospital admissions, the duration of the present hospital admission prior to entry into the study unit, and recent antibiotic administration. An episode in a patient who transferred between study wards was considered a single study episode, but episodes in a patient who was absent from a study ward for longer than 1 day and who was then subsequently readmitted to a study ward were recorded as two separate study episodes. Study end points were (i) identification of colonization or infection with VRE (Enterococcus faecalis or Enterococcus faecium) or (ii) departure from the study unit. Antibiotic monitoring. The use of antibiotics, especially the use of glycopeptides, broad-spectrum (ceftriaxone, cefotaxime, and ceftazidime), and newer (cefepime and cefpirome) cephalosporins, carbapenems, metronidazole, fluoroquinolones, gentamicin, ampicillin-amoxicillin, ticarcillin, or ticarcillin-clavulanic acid, was recorded prospectively by ward pharmacists during each admission to a study area. The number of days during which patients were likely to have detectable serum antibiotic concentrations following administration of the last dose of a monitored antibiotic were estimated by using the schedule outlined in Table 1. Thus, the total number of days of antibiotic exposure was calculated for each patient, with antibiotic exposures adjusted for renal impairment. Recent antibiotic exposure was considered to have occurred if antibiotics were administered either within 7 days of a study end point or if detectable serum antibiotic levels could be expected within this time period. Protocol for culture of VRE. The protocol for cultures of rectal swab specimens for VRE specified that a specimen for culture be collected by the managing nurse or doctor at the time of admission to the study (or within 2 days) and then every 7 days ( 2 days). Given the busy clinical nature of the study units and in line with earlier studies, it was expected that adherence to this screening protocol was likely to be a challenge and that strict adherence to this screening protocol was likely to decline with an increasing duration of study participation. Hence, the adequacy of protocol adherence for each patient was classified according to the following definitions: optimal adherence was complete adherence to the swabbing protocol, and acceptable adherence was retrieval of a specimen for culture upon admission, followed by adherence to the protocol except for an occasional lack of collection of specimens for culture. In such cases there could be no greater than 14 ( 2) days between cultures of rectal swab specimens (i.e., one missed culture), and for patients who were found to be rectally colonized with VRE, a negative rectal swab specimen for culture was required 7 ( 2) days prior to the first positive culture for VRE. Thus, patients who were considered to have undergone optimal screening were a subset of those who were considered to have had acceptable screening. Unacceptable adherence was a protocol violation in excess of those defined as acceptable. Only patients who underwent either optimal or acceptable screening were evaluated for factors that may potentially be associated with colonization or infection with VRE. All analyses were conducted with these study subpopulations. Patients were censored when they became colonized with VRE. Microbiology cultures and clonality. Rectal swabs were directly inoculated onto Enterococcosel agar (BBL, Cockeysville, Md.) containing 6 g of vancomycin per ml and were incubated at 35 C for 48 to 72 h. Esculin-positive colonies (three isolates of each morphological appearance) were investigated and provisionally identified as E. faecium or E. faecalis on the basis of routine criteria (gram-positive cocci, L-pyrrolidonyl- -naphthylamide hydrolase positive, nonmotile, catalase negative, and pigment negative) (15). Isolates fulfilling these criteria were assessed for susceptibility to vancomycin by the E-test (AB Biodisk, Dalvagen, Sweden). Isolates for which the vancomycin MIC was 2 g/ml were analyzed for the presence of the vana, vanb, vanc1, or vanc2-vanc3 gene by PCR; and isolates positive for the vana or vanb gene were then confirmed to be either E. faecium or E. faecalis by PCR (1, 13). Isolates containing vanc genes were not assessed further or recorded. The molecular clonality of all VRE isolates was assessed by pulsed-field gel electrophoresis (PFGE), and differences were compared according to the criteria described previously (22, 30). The PFGE patterns of the study isolates were compared with each other and with those of the clinical strains of VRE known to be most commonly responsible for colonization and infection in Melbourne (17, 24). All participating institutions followed identical screening and microbiology protocols. Ethics approval. The ethics committee at each of the three institutions approved the study protocol. Since the study protocol represented a relatively minor expansion of the infection control screening program already in place at each institution, only verbal patient consent was required. Statistical analyses. The impact of hospital admission during the 3-month period prior to study entry on the likelihood that patients would be found to be colonized with VRE at the time of study admission was assessed by using the Pearson chi-square statistic. Analyses were performed for patients who were not colonized with VRE on admission and who achieved optimal or acceptable adherence with the screening protocol. The rate of acquisition of VRE was defined as the number of new cases of colonization with VRE divided by the total number of days of patient exposure until a study end point was reached. Among patients who became colonized with VRE, this duration of exposure was from the time of study admission to the day that the patient was first found to be colonized with VRE. For patients who did not become colonized with VRE, exposure time was calculated from the time of study admission until the date of the final negative rectal swab specimen culture. The potential impacts of various factors including, patient sex, comorbidities, managing unit, and recent antibiotic exposure on the rates of acquisition of VRE were assessed by use of the Cox proportional hazards regression model for univariate and multivariate analyses. Variables with P values of 0.2 in the univariate analysis were included in the multivariate analysis. Standard errors for these incidence rates were calculated by the jackknife method (5) to account for a likely correlation between multiple admissions for the same patient. If no events were observed in a group, the Poisson approximation method was used to calculate standard errors (Statcorp 1999; Stata statistical software, release 6.0;

3 2494 PADIGLIONE ET AL. ANTIMICROB. AGENTS CHEMOTHER. Hospital and unit TABLE 2. New cases of VRE colonization Patients No. (%) of: Stata Corporation, College Station, Tex.). A P value of 0.05 was considered statistically significant. RESULTS Admissions No. of rectal swab specimens in which VRE were detected on: Initial culture Subsequent culture AH ICU, general 496 (14) 513 (12) 9 5 ICU, road trauma 405 (11) 414 (10) 2 a 0 ICU, cardiothoracic 821 (23) 842 (20) 3 7 Renal 130 (4) 178 (4) 0 1 Heart-lung transplant 124 (4) 163 (4) 0 4 ARMC ICU 403 (12) 423 (10) 3 2 Renal 288 (8) 525 (12) 5 11 Liver transplant 34 (1) 39 (1) 2 2 MMC ICU 187 (5) 191 (5) 1 0 Renal 321 (9) 495 (12) 2 3 Hematology-oncology 285 (8) 432 (10) 4 0 Total 3,494 4, a For both specimens, VRE were detected in swabs recovered after a delay. No road trauma patients for whom a rectal swab specimen was cultured (n 342) within 2 days of admission was colonized with VRE. During the 15-month study 8,953 rectal swab specimens were obtained from 3,458 patients during 4,215 admissions. Only 16% of patients had repeat admissions during the study. For most patients (n 2,103; 50%) the result for only one rectal swab specimen was assessed; but for 1,168 (28%) patients two rectal swab specimens were assessed, for 419 (10%) patients three rectal swab specimens were assessed, and for 525 (12%) patients four or more rectal swab specimens were assessed. This swabbing frequency was expected given the typical lengths of stay observed for these patients (the median length of stay at each study site was 7 days). Adherence to the swabbing protocol was generally good, with 93% of the intervals between the collection of swab specimens being 8 days and only 1.4% of the intervals being greater than 16 days. The majority of patients (66%) were admitted directly to a study ward. However, 5% of patients were in a hospital for more than 10 days before they entered a study ward. No clinical infections with VRE occurred at any study site during the trial period. However, 66 patients were found to be colonized with VRE (Table 2; vanb E. faecium, 71%; vanb E. faecalis, 21%; vana E. faecium, 6%; vana E. faecalis, 2%). The vancomycin and teicoplanin susceptibilities of these isolates were typical of those for vana isolates (MIC, 256 g of vancomycin per ml) or vanb isolates (range, 4 to 256 g of vancomycin per ml). Notably, most strains of VRE were nonclonal on PFGE analysis. A total of 56 of the 66 isolates (85%) from patients found to be colonized with VRE were subjected to PFGE analysis, and 33 different PFGE patterns were identified among the 56 isolates. Data for patients with acceptable adherence are shown in Table 3. Among the 3,086 cases (2,612 patients) for which a rectal swab specimen was obtained within 2 days of study admission, 19 were colonized with VRE, suggesting an overall baseline prevalence of 0.6%. The risk of colonization with VRE increased with time spent in a hospital prior to entry into a study unit: the prevalence of colonization with VRE was 0.4% for cases admitted directly to a study unit, 0.8% if cases had been in a hospital 1 to 8 days prior to study entry, and 1.9% if cases had been in a hospital for 8 days prior to entry into a study unit. Among acute trauma patients who were admitted from the community directly to the trauma ICU (n 342), none were colonized with VRE. In contrast, among the 437 cases that had had a previous admission to a study site during the preceding 3 months, 1.4% (95% confidence interval [CI] for relative risk, 1.1 to 7.3 [P 0.03]) were colonized with VRE at admission. Interpretation of the status of acquisition of VRE among patients from whom a baseline rectal swab specimen was not obtained (unacceptable screening) was difficult. The limited analysis that could be undertaken suggested that the rate of colonization with VRE increased with the duration of inpatient stay at the study sites. Among 954 cases initially swabbed 3 to 8 days after study admission, 8 (0.8%) were colonized, whereas 4 of 175 (2.3%) cases that were first swabbed more than 8 days after study admission were colonized. Acquisition of VRE was observed for 35 patients who had negative initial baseline rectal swab specimen cultures. Of these patients, 24 had undergone acceptable screening (and 13 of these had optimal screening adherence) (Tables 2 and 3). Acceptable screening occurred for 1,992 admissions (and optimal screening occurred for 1,553 admissions), accounting for a total of 16,881 days at risk. Thus, the rate of acquisition of colonization with VRE among the group with acceptable screening was 24 of 16,881, or 1.4 cases per 1,000 days of person-time at risk (95% CI, 1.0 to 2.2). This rate was similar if only the patients who had optimal screening were considered (data not shown). The timing of acquisition of VRE among patients with acceptable screening is shown in Table 3. The results of univariate and multivariate analyses of patient risk factors for the acquisition of VRE are shown in Table 4. Patients managed by renal units appeared to have a significantly higher risk of acquisition than patients managed by other units. Although univariate analysis suggested that previous admission to a study site within the past 3 months was significantly associated with the acquisition of VRE, this was not confirmed on multivariate analysis. Sex, the presence of liver failure or renal impairment, diabetes, or organ transplantation was not associated with the acquisition of VRE. Antibiotic use was common in our study population, especially the use of glycopeptides and cephalosporins. Among the 1,992 admissions that had acceptable adherence to the rectal swab specimen culture protocol, glycopeptides were used in 614 (31%); broad-spectrum cephalosporins were used in 688 (35%); carbapenems were used in 329 (17%); ticarcillin-clavulanic acid was used in 195 (10%); ampicillin, gentamicin, or ciprofloxacin was used in 503 (26%); and metronidazole was used in 328 (17%). Piperacillin-tazobactam (0.1%), cefepime (0.3%), and cefpirome (0.3%) were rarely used. Of the broad-spectrum cephalosporins, ceftriaxone (48%) was the most commonly used, followed by cefo-

4 VOL. 47, 2003 VRE IN HOSPITALS WITH STRICT INFECTION CONTROL POLICIES 2495 TABLE 3. Timing of acquisition of VRE among patients with both optimal and acceptable adherence to rectal swab specimen culture protocol Patient no. a Detection on study dayb : X A 2 X B 3 X C 4 X * 5 X * 6 X D 7 X X E 8 X * 9 X F 10 X X E 11 X X G 12 X X E 13 X X X X X X X X X X X X H 14 X E 15 X C 16 X I 17 X J 18 X X K 19 X X L 20 X X X M 21 X X X X X X X X X X N 22 X X X X X X X X X * 23 X X X X X X X X E 24 X X X X X X X X X X X X X X X X X X X O a Patients 1 to 13 underwent the optimal rectal swab specimen culture protocol. b X, no VRE detected on rectal swab specimen culture;, VRE detected on rectal swab specimen culture; superscripts A to O, PFGE data, in which different letters represent different strains, based on three band differences; *, not tested. Results for 2-day intervals are given for ease of comprehension. taxime (35%) and ceftazidime (17%). However, we did not show an association between the use of glycopeptides or broadspectrum cephalosporins and the new detection of VRE (Table 4). Instead, the strongest association with the development of colonization with VRE was noted with the recent use of ticarcillin-clavulanic acid. Administration of this agent was highly associated with colonization by multivariate analysis of both the acceptable and optimal screening groups (for the acceptable screening group, the hazard ratio [HR] was 3.6 and the 95% CI was 1.13 to 11.6; for the optimal screening group, HR was 6.4 and the 95% CI was 3.7 to 36.6 [P 0.03 and 0.001, respectively]). By multivariate analysis, recent carbapenem administration was also associated with colonization with VRE among patients in the acceptable screening group (HR, 2.8; 95% CI, 1.0 to 8.0 [P 0.048]). A post hoc analysis of patients in the acceptable screening group was undertaken to assess any difference in the impacts of antibiotics with activity against anaerobes (ticarcillin-clavulanic acid, piperacillin-tazobactam, meropenem, imipenem, and metronidazole) compared with the impacts of those with no activities against anaerobes. This demonstrated a significant association between the use of antibiotics with activities against anaerobes and the new detection of VRE (by univariate analysis, HR was 2.21 and the 95% CI was 0.82 to 5.96 [P 0.12]; by multivariate analysis, HR was 3.34 and the 95% CI was 1.4 to 7.73 [P 0.01]). DISCUSSION This is one of the largest prospective studies to assess colonization with VRE in institutions in which the risk of nosocomial transmission of VRE had been minimized by the strict enforcement of infection control and isolation procedures. We especially aimed to accurately identify risk factors that were associated with the new detection of VRE, particularly the new emergence of VRE or the unmasking of preexisting low-level colonization rather than the nosocomial spread of VRE. The prospective cohort design also allowed us to control for the potential confounding effects of duration of exposure. Overall, we found that 1.56% of cases (1.91% patients) were colonized with VRE, with an acquisition rate of 1.4 patients per 1,000 patient days in study units. Our findings are consistent with previous Australian data and for a number of reasons suggest that we did in fact largely control for nosocomial transmission. First, the 1.56% overall rate of colonization with VRE is substantially lower than that from a previous report, in which 4.6% of high-risk patients were colonized following an outbreak of VRE in one of the study institutions (17). This rate of colonization is substantially less than that described in many U.S. and European studies (6, 31, 35). Second, consistent with previous Australian reports and unlike the epidemiology of VRE most commonly reported from the United States and Europe, we found vanb strains of VRE, especially vanb E. faecium strains, to be the most commonly isolated species (1, 3, 17, 25). Most importantly, the vast majority of our isolates appeared to be nonclonal by PFGE and to only infrequently be the clones responsible for most cases of colonization with VRE and disease caused by VRE in Melbourne (G. Hogg, personal communication). This observation is consistent with the view that the strict infection control measures in place at each study site were largely effective in controlling the nosocomial transmission of VRE. The low overall rate (0.6%) of carriage of VRE at admis-

5 2496 PADIGLIONE ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 4. Risk factors for new colonization with VRE among patients adherent to acceptable culture protocol Risk factor New cases of VRE (n 24) No. (%) of Univariate analysis Multivariate analysis Controls (n 1,968) Sex, male 15 (62) 1,279 (65) , HR 95% CI P value HR 95% CI P value Presence of: Diabetes 8 (33) 360 (18) , Immunosuppression 4 (17) 401 (20) , Dialysis 11 (46) 327 (17) , , Renal failure 10 (42) 443 (23) , Liver failure 3 (12) 137 (7) , Transplantation 2 (8) 176 (89) , Previous admission within 3 mo 9 (37) 305 (15) , , Managing unit: Intensive care a 7 (29) 1234 (63) 1 Renal 13 (54) 429 (22) , , b Transplant (liver, heart/lung) 4 (17) 102 (5) , , Haematology/oncology (10) Antibiotic use Any antibiotic 19 (79) , Glycopeptide(s) 13 (54) , c , Broad-spectrum cephalosporin(s) g 4 (17) , Imipenem, meropenem 8 (33) , d , d Ticarcillin-clavulanate 4 (17) , e , e Ampicillin, gentamicin, ciprofloxacin f 6 (25) , Metronidazole 4 (17) , a Management by ICU was used as the comparator; therefore, HR was equal to 1. b For the 13 patients adherent to the optimal culture protocol, HR was 4.26 (95% CI, 1.26 to 14.5 [P 0.02]) by univariate analysis and HR was 10.9 (95% CI, 1.6 to 74 [P 0.014]) by multivariate analysis. c For the 13 patients adherent to the optimal culture protocol, HR was 0.96 (95% CI, 0.29 to 3.31 [P 0.94]) by univariate analysis. d For the 13 patients adherent to the optimal culture protocol, HR was 1.44 (95% CI, 0.31 to 6.63 [P 0.64]) by univariate analysis; therefore, data for this population were not evaluated by multivariate analysis. e For the 13 patients adherent to the optimal culture protocol, HR was 4.86 (95% CI, 1.65 to [P 0.004]) by univariate analysis and HR was 6.44 (95% CI, 3.63 to 36.6 [P 0.001]) by multivariate analysis. f Patients receiving any of these antibiotics were analyzed together because these agents have only limited activities against anaerobic organisms. g Ceftriaxone, cefotaxime, and ceftazidime. sion, the even lower rate of carriage among the subset of patients new to the study, and the fact that no colonization with VRE was detected among any acute trauma patients directly admitted to the major trauma ICU support the view that colonization with VRE is uncommon in the general Australian community. We have previously suggested that the community rate of carriage of VRE is only 0.2%, unlike in Europe, where community colonization rates of 8 to 23% have been reported (14, 16, 21, 25, 33, 34). Multivariate analysis of our data suggested that the potential risk factors for the new detection of VRE were being managed by a renal unit and being treated with a broad-spectrum agent, ticarcillin-clavulanic acid or a carbapenem. These data are consistent with those from previous reports (26). The association between the recent administration of ticarcillin-clavulanic acid (and possibly carbapenems) and the new detection of VRE provides important in vivo support for humans of the animal studies conducted by Donskey et al. (10, 11), in which drugs with broad-spectrum activities (notably, ticarcillin-clavulanic acid) appeared to be linked to both the establishment and the persistence of colonization with VRE. Similarly, other studies by those investigators (9) have suggested that antibiotic regimens with activity against anaerobes promote the density of colonization with VRE in the human gastrointestinal tract, although those studies did not specifically assess the role of ticarcillin-clavulanic acid. Importantly, our patient-specific antibiotic data confirm the association found between hospitalwide VRE infection rates and hospital purchasing data for ticarcillin-clavulanic acid (12). A number of studies have noted a high rate of colonization with VRE among renal patients (21, 27). We did not find an association between the new detection of VRE and recent administration of either broad-spectrum cephalosporins or vancomycin. There may be a number of potential reasons for this observation. First, as was well described in the recent review by Harbath et al. (18), the factors associated with acquisition of VRE are often complex, may be confounded by local variables, and may be different depending on whether the patient acquires VRE by nosocomial transmission or by primary in vivo emergence (e.g., gene transfer to previously susceptible enterococci). Second, our attempt to predict and adjust for the likely impact of renal dysfunction on the potential time during which patients had detectable serum antibiotic concentrations may have influenced our analysis. We believe this to be an important feature of any studies such as ours, since it provides a more accurate assessment of the likely duration of exposure during which the patients normal floras are exposed to selective antibiotic pressure. However, few

6 VOL. 47, 2003 VRE IN HOSPITALS WITH STRICT INFECTION CONTROL POLICIES 2497 other studies assessing risk factors for colonization with VRE or disease caused by VRE have controlled for this variable. Finally, our study may have been too small to detect such an association. Our findings of largely nonclonal strains of VRE, the generally delayed timing of detection of VRE, and the association with recent antibiotic therapy are consistent with our reported hypothesis regarding the emergence of VRE. We have previously identified vanb genes in a number of naturally occurring fecal anaerobes and have proposed that VRE may emerge under appropriate selective conditions when vanb genes are transferred to susceptible enterococci in the human gut. Subsequently, nosocomial transmission may result in the spread of some clones (29). While the findings of this study are consistent with this hypothesis, formal evidence of gene transfer is still required. Our study has a number of limitations. First, the epidemiology of VRE in Australia appears to be different from that in Europe and the United States (1, 24). Our findings may not be applicable to other regions. In particular, the fact that colonization with VRE appears to be uncommon in the general Australian community and the fact that VRE are not endemic in most Australian hospitals are notable (25). Furthermore, risk factors associated with colonization with VRE among high-risk patients may be different for patients not managed by such specialized units. Second, the number of patients who were colonized with VRE and who had acceptable adherence to the screening program was relatively limited (n 24). Thus, only a relatively limited proportion of the total number of patients colonized with VRE identified (n 66) could be accurately assessed for risk factors associated with colonization with VRE. This finding highlights the difficulty in maintaining adherence to such clinical study protocols in busy acute-care hospitals where high-risk patients are usually found. Adherence difficulties may also have affected our assessment of risk factors for colonization with VRE. For instance, recent administration of carbapenems was significantly associated with colonization with VRE among patients with acceptable screening adherence but was not significantly associated with colonization with VRE among patients who had optimal screening, probably due to the smaller number of cases with newly detected colonization with VRE. We believe that since PFGE analysis of our VRE strains suggested that most isolates were nonclonal, the strict infection control procedures that were in place at each study site were reasonably effective in preventing the nosocomial transmission of dominant clones. Nevertheless, the fact that some strains had similar PFGE patterns suggests that we cannot exclude some hospital-related transmission of VRE. Given the recent findings by D Agata et al. (7) regarding the potential rate of false-negative results for rectal swab specimen cultures for the detection of fecal carriage of VRE, we cannot be absolutely certain that some of our patients who appeared to have become colonized with VRE after study admission may not have actually already been colonized at the time of study entry. Apart from the inherent potential sampling error associated with rectal swab specimen cultures, some variability in culture technique is possible, although, it is hoped, limited. Fecal culture for the detection of VRE would probably have been more accurate, but this would have been impractical within the study sites and the patient population assessed (7). Harbath et al. (18) have highlighted the large number of variables that may be associated with colonization with VRE and the difficulty in assessing and controlling for all potential confounding factors. Nevertheless, given the size and circumstances of our study, we believe that we have accurately identified risk factors associated with colonization with vanb strains of VRE. Our study suggests that strict infection control and isolation procedures are effective in controlling nosocomial transmission. ACKNOWLEDGMENTS We thank the microbiology, pharmacy, and nursing staffs and the patients of the three institutions that participated in the study and Geoff Hogg and the staff at the Microbiological Diagnostic Unit, University of Melbourne, for the PFGE analysis. This study was funded in part by a grant from the Department of Human Services of Victoria, Australia. REFERENCES 1. Bell, J., J. Paton, and J. Turnidge Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates J. Clin. Microbiol. 36: Bennett, W. M Drug prescribing in renal failure, 3rd ed. American College of Physicians, Philadelphia, Pa. 3. Centers for Disease Control and Prevention Nosocomial enterococci resistant to vancomycin United States, Morb. Mortal. Wkly. Rep. 42: Centers for Disease Control and Prevention Guidelines for isolation precautions in hospitals. Am. J. Infect. Control 24: Clayton, D., and M. Hills Statistical models in epidemiology. Oxford University Press, Oxford, United Kingdom. 6. Coque, T., J. F. Tomayko, S. C. Ricke, P. C. Okyusen, and B. E. Murray Vancomycin-resistant enterococci from nosocomial community and animal sources in the United States. Antimicrob. Agents Chemother. 40: D Agata, E. M., S. Gautam, W. K. Green, and Y. W. Tang High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin. Infect. Dis. 34: Dan, M., F. Poch, L. Leibson, S. Smetana, and I. Priel Rectal colonization with vancomycin-resistant enterococci among high-risk patients in an Israeli hospital. J. Hosp. Infect. 43: Donskey, C. J., T. K. Chowdhry, M. T. Hecker, C. K. Hoyen, J. A. Hanrahan, A. M. Hujer, R. A. Hutton-Thomas, C. C. Whalen, R. A. Bonomo, and L. B. Rice Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343: Donskey, C. J., J. A. Hanrahan, R. A. Hutton, and L. B. Rice Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J. Infect. Dis. 180: Donskey, C. J., J. A. Hanrahan, R. A. Hutton, and L. B. Rice Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J. Infect. Dis. 181: Donskey, C. J., J. R. Schreiber, M. R. Jacobs, R. Shekar, R. A. Salata, S. Gordon, C. C. Whalen, F. Smith, L. B. Rice, et al A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Clin. Infect Dis. 29: Dutka-Malen, A., S. Evers, and P. Courvalin Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33: Endtz, H. P., N. van den Braak, A. van Belkum, J. A. Kluytmans, J. G. Koeleman, L. Spanjaard, A. Voss, A. J. Weersink, C. M. Vandenbroucke- Grauls, A. G. Buiting, A. van Duin, and H. A. Verbrugh Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands. J. Clin. Microbiol. 35: Facklam, R. R., D. Sahm, and L. M. Teixeira Enterococcus, p In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C. 16. Gambarotto, K., M. C. Ploy, P. Turlure, C. Grelaud, C. Martin, D. Bordessoule, and F. Denis Prevalence of vancomycin-resistant enterococci in

7 2498 PADIGLIONE ET AL. ANTIMICROB. AGENTS CHEMOTHER. fecal samples from hospitalized patients and nonhospitalized controls in a cattle-rearing area of France. J. Clin. Microbiol. 38: Grayson, M. L., E. A. Grabsch, P. D. Johnson, D. Olden, M. Aberline, H. Y. Li, G. Hogg, M. Abbott, and P. G. Kerr Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria. Med. J. Aust. 171: Harbath, S., S. Cosgrove, and Y. Carmeli Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 46: Harris, A. D., T. B. Karchmer, Y. Carmeli, and M. H. Samore Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 32: Hospital Infection Control Practices Advisory Committee Recommendations for preventing the spread of vancomycin resistance. Infect. Control Hosp. Epidemiol. 16: Jordens, J. Z., J. Bates, and D. T. Griffiths Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J. Antimicrob. Chemother. 34: Miranda, A. G., K. V. Singh, and B. E. Murray DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool. J. Clin. Microbiol. 29: Moreno, F., P. Grota, C. Crisp, K. Magnon, G. P. Melcher, J. H. Jorgensen, and J. E. Patterson Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas. Clin. Infect. Dis. 21: Padiglione, A., E. Grabsch, R. Wolfe, K. Gibson, and M. L. Grayson The prevalence of fecal colonization with VRE among residents of longterm-care facilities in Melbourne, Australia. Infect. Control Hosp. Epidemiol. 22: Padiglione, A. A., E. A. Grabsch, D. Olden, M. Hellard, M. I. Sinclair, C. K. Fairley, and M. L. Grayson Fecal colonisation with vancomycinresistant enterococci in Australia. Emerg. Infect. Dis. 6: Rice, L. B Emergence of vancomycin-resistant enterococci. Emerg. Infect. Dis. 7: Roghmann, M. C., J. C. Fink, L. Polish, T. Maker, J. Brewrink, J. G. Morris, and P. D. Light Colonisation with vancomycin-resistant enterococci in chronic haemodialysis patients. Am. J. Kidney Dis. 32: Standing Committee on Infection Control Guidelines for the management of patients with vancomycin-resistant enterococci (VRE) colonisation/infection. Department of Human Services, Melbourne, Australia Stinear, T. P., D. C. Olden, P. D. Johnson, J. K. Davies, and M. L. Grayson Enterococcal vanb resistance locus in anaerobic bacteria in human faeces. Lancet 357: Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33: Tokars, J. I., S. Satake, D. Rimland, L. Carson, E. R. Miller, E. Killum, R. L. Sinkowitz-Cochran, M. J. Arduino, F. C. Tenover, B. Marston, and W. R. Jarvis The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans Affairs institution. Infect. Control Hosp. Epidemiol. 20: Tornieport, N. G., R. B. Roberts, J. John, A. Hafner, and L. W. Riley Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin. Infect. Dis. 23: van den Bogaard, A. E., L. B. Jensen, and E. E. Stobberingh Vancomycin-resistant enterococci in turkeys and farmers. N. Engl. J. Med. 337: Van der Auwera, P., N. Pensart, V. Korten, B. Murray, and R. Leclercq Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J. Infect. Dis. 173: Wells, C. L., B. A. Juni, S. B. Cameron, K. R. Mason, D. L. Dunn, P. Ferrieri, and F. S. Rhame Stool carriage, clinical isolation, and mortality during an outbreak of VRE in hospitalized medical and/or surgical patients. Clin. Infect. Dis. 21:45 50.

Decrease of vancomycin resistance in Enterococcus faecium from bloodstream infections in

Decrease of vancomycin resistance in Enterococcus faecium from bloodstream infections in AAC Accepted Manuscript Posted Online 30 March 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.00513-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 Decrease of vancomycin

More information

Research Article Risk Factors Associated with Vancomycin-Resistant Enterococcus in Intensive Care Unit Settings in Saudi Arabia

Research Article Risk Factors Associated with Vancomycin-Resistant Enterococcus in Intensive Care Unit Settings in Saudi Arabia Interdisciplinary Perspectives on Infectious Diseases Volume 2013, Article ID 369674, 4 pages http://dx.doi.org/10.1155/2013/369674 Research Article Risk Factors Associated with Vancomycin-Resistant Enterococcus

More information

Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study

Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study Karki et al. Antimicrobial Resistance and Infection Control 2012, 1:31 RESEARCH Open Access Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional

More information

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply. Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted

More information

Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10

Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

Jump Starting Antimicrobial Stewardship

Jump Starting Antimicrobial Stewardship Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing

More information

Driving forces of vancomycin-resistant E. faecium and E. faecalis blood-stream infections in children

Driving forces of vancomycin-resistant E. faecium and E. faecalis blood-stream infections in children Di Pentima et al. Antimicrobial Resistance and Infection Control 2014, 3:29 RESEARCH Open Access Driving forces of vancomycin-resistant E. faecium and E. faecalis blood-stream infections in children Maria

More information

Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis

Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis Journal of Antimicrobial Chemotherapy (2004) 53, 626 630 DOI: 10.1093/jac/dkh138 Advance Access publication 18 February 2004 Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis

More information

Evaluating the Role of MRSA Nasal Swabs

Evaluating the Role of MRSA Nasal Swabs Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization

More information

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and

More information

Fecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin

Fecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin ISPUB.COM The Internet Journal of Infectious Diseases Volume 2 Number 2 Fecal Emergence of Vancomycin-Resistant Enterococci after Prophylactic Intravenous Vancomycin E Nahum, Z Samra, J Ben-Ari, O Dagan,

More information

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST

More information

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.

More information

Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship

Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases

More information

Drive More Efficient Clinical Action by Streamlining the Interpretation of Test Results

Drive More Efficient Clinical Action by Streamlining the Interpretation of Test Results White Paper: Templated Report Comments Drive More Efficient Clinical Action by Streamlining the Interpretation of Test Results Background The availability of rapid, multiplexed technologies for the comprehensive

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

against Clinical Isolates of Gram-Positive Bacteria

against Clinical Isolates of Gram-Positive Bacteria ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,

More information

Should we test Clostridium difficile for antimicrobial resistance? by author

Should we test Clostridium difficile for antimicrobial resistance? by author Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first

More information

Other Enterobacteriaceae

Other Enterobacteriaceae GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known

More information

Two (II) Upon signature

Two (II) Upon signature Page 1/5 SCREENING FOR ANTIBIOTIC RESISTANT ORGANISMS (AROS) IN ACUTE CARE AND LONG TERM CARE Infection Prevention and Control IPC 050 Issuing Authority (sign & date) Office of Administrative Responsibility

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required

More information

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic

More information

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity

More information

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant

More information

Int.J.Curr.Microbiol.App.Sci (2017) 6(3):

Int.J.Curr.Microbiol.App.Sci (2017) 6(3): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104

More information

Is Clostridium difficile infection influenced by antimicrobial use density in wards?

Is Clostridium difficile infection influenced by antimicrobial use density in wards? Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 87 29 Is Clostridium difficile infection influenced by antimicrobial use density in wards? NOBUMICHI OGAMI, JUNICHI YOSHIDA, TOSHIYUKI ISHIMARU, TETSUYA

More information

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of

More information

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Enterococcal Species

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Enterococcal Species GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 44 Enterococcal Species Authors Jacob Pierce, MD, Michael Edmond, MD, MPH, MPA Michael P. Stevens, MD, MPH Chapter Editor Victor D. Rosenthal, MD, CIC,

More information

Empiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital

Empiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital Original Article Brunei Int Med J. 2013; 9 (6): 372-377 Empiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital Lah Kheng CHUA, Department of Pharmacy, RIPAS Hospital,

More information

Antimicrobial utilization: Capital Health Region, Alberta

Antimicrobial utilization: Capital Health Region, Alberta ANTIMICROBIAL STEWARDSHIP Antimicrobial utilization: Capital Health Region, Alberta Regionalization of health care services in Alberta began in 1994. In the Capital Health region, restructuring of seven

More information

Exploring the Role of Antibiotics on VRE Colonization and Infection

Exploring the Role of Antibiotics on VRE Colonization and Infection Exploring the Role of Antibiotics on VRE Colonization and Infection Dr. James McKinnell, Dr. Loren Miller, Dr. Arnold Bayer K30 Fellow Harbor-UCLA/University of Alabama Background Enterococcus Spp. are

More information

Frank Møller Aarestrup

Frank Møller Aarestrup Danish Veterinary Laboratory Bacterial populations and resistance development: Intestinal tract of meat animals Frank Møller Aarestrup 12 Antibiotic production 10 Mill. Kg 8 6 4 2 0 50 52 54 56 58 60 62

More information

Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization

Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization

More information

Antimicrobial-Resistant, Gram-Positive Bacteria among Patients Undergoing Chronic Hemodialysis

Antimicrobial-Resistant, Gram-Positive Bacteria among Patients Undergoing Chronic Hemodialysis ANTIMICROBIAL RESISTANCE George Eliopoulos, Section Editor INVITED ARTICLE Antimicrobial-Resistant, Gram-Positive Bacteria among Patients Undergoing Chronic Hemodialysis Erika M. C. D Agata Division of

More information

Surveillance of Multi-Drug Resistant Organisms

Surveillance of Multi-Drug Resistant Organisms Surveillance of Multi-Drug Resistant Organisms Karen Hoffmann, RN, MS, CIC Associate Director Statewide Program for Infection Control and Epidemiology (SPICE) University of North Carolina School of Medicine

More information

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique

More information

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental

More information

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

MRSA in the United Kingdom status quo and future developments

MRSA in the United Kingdom status quo and future developments MRSA in the United Kingdom status quo and future developments Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017. Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing

More information

Randall Singer, DVM, MPVM, PhD

Randall Singer, DVM, MPVM, PhD ANTIBIOTIC RESISTANCE Randall Singer, DVM, MPVM, PhD Associate Professor of Epidemiology Department of Veterinary and Biomedical Sciences University of Minnesota Overview How does resistance develop? What

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

FM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...

FM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment... Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo

More information

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?

More information

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE (DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE John Ferguson (Hunter New England, NSW) on behalf of MRGN Task Force Acknowledgement

More information

The importance of infection control in the era of multi drug resistance

The importance of infection control in the era of multi drug resistance Dr. Kumar Consultant Infectious Diseases Physician Hospital Sungai buloh The importance of infection control in the era of multi drug resistance Nosocomial infections In Australian acute hospitals 200,000

More information

Informing Public Policy on Agricultural Use of Antimicrobials in the United States: Strategies Developed by an NGO

Informing Public Policy on Agricultural Use of Antimicrobials in the United States: Strategies Developed by an NGO Informing Public Policy on Agricultural Use of Antimicrobials in the United States: Strategies Developed by an NGO Stephen J. DeVincent, DVM, MA Director, Ecology Program Alliance for the Prudent Use of

More information

Carbapenemase-Producing Enterobacteriaceae (CPE)

Carbapenemase-Producing Enterobacteriaceae (CPE) Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)

More information

EVOLUTION OF THE ENDOGEN FLORA SUSCEPTIBILITY PROFILES AMONG MEDICAL STUDENTS IN ACCORDANCE WITH THEIR YEAR OF STUDY

EVOLUTION OF THE ENDOGEN FLORA SUSCEPTIBILITY PROFILES AMONG MEDICAL STUDENTS IN ACCORDANCE WITH THEIR YEAR OF STUDY EVOLUTION OF THE ENDOGEN FLORA SUSCEPTIBILITY PROFILES AMONG MEDICAL STUDENTS IN ACCORDANCE WITH THEIR YEAR OF STUDY G E B R A E L S A L I B A, M D, M P H C L I N H D F 2017 U N I V E R S I T É S A I N

More information

ANTIMICROBIAL SUSCEPTIBILITY VANCOMYCIN RESISTANCE IN AN UNCOMMON ENTEROCOCCAL SPECIES

ANTIMICROBIAL SUSCEPTIBILITY VANCOMYCIN RESISTANCE IN AN UNCOMMON ENTEROCOCCAL SPECIES ENTEROCOCCAL SPECIES Sample ES-02 was a simulated blood culture isolate from a patient with symptoms of sepsis. Participants were asked to identify any potential pathogen and to perform susceptibility

More information

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,

More information

Nosocomial Infections: What Are the Unmet Needs

Nosocomial Infections: What Are the Unmet Needs Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com

More information

Summary of the latest data on antibiotic resistance in the European Union

Summary of the latest data on antibiotic resistance in the European Union Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network

More information

b-lactam Antibiotics and Gastrointestinal Colonization with Vancomycin-Resistant Enterococci

b-lactam Antibiotics and Gastrointestinal Colonization with Vancomycin-Resistant Enterococci MAJOR ARTICLE b-lactam Antibiotics and Gastrointestinal Colonization with Vancomycin-Resistant Enterococci Louis B. Rice, 1,2,3 Rebecca Hutton-Thomas, 1 Viera Lakticova, 2 Marion S. Helfand, 1 and Curtis

More information

Background and Plan of Analysis

Background and Plan of Analysis ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification

More information

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Measurement of Antimicrobial Drug Use. Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist

Measurement of Antimicrobial Drug Use. Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist Measurement of Antimicrobial Drug Use Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS DASON Liaison Pharmacist Defined Daily Dose Target Audience: Administrators and Epidemiologists Standardized definition

More information

ORIGINAL INVESTIGATION. The Role of Colonization Pressure in the Spread of Vancomycin-Resistant Enterococci

ORIGINAL INVESTIGATION. The Role of Colonization Pressure in the Spread of Vancomycin-Resistant Enterococci The Role of Colonization Pressure in the Spread of Vancomycin-Resistant Enterococci An Important Infection Control Variable ORIGINAL INVESTIGATION Marc J. M. Bonten, MD; Sarah Slaughter, MD; Anton W. Ambergen;

More information

Antimicrobial Stewardship Program: Local Experience

Antimicrobial Stewardship Program: Local Experience Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH

More information

BMC Infectious Diseases

BMC Infectious Diseases BMC Infectious Diseases This Provisional PDF corresponds to the article as it appeared upon acceptance. Copyedited and fully formatted PDF and full text (HTML) versions will be made available soon. Staphylococcus

More information

PREVALENCE OF ANTIMICROBIAL RESISTANCE IN ENTEROCOCCUS ISOLATES IN AUSTRALIA, 2005:

PREVALENCE OF ANTIMICROBIAL RESISTANCE IN ENTEROCOCCUS ISOLATES IN AUSTRALIA, 2005: PREVALENCE OF ANTIMICROBIAL RESISTANCE IN ENTEROCOCCUS ISOLATES IN AUSTRALIA, 25: REPORT FROM THE AUSTRALIAN GROUP ON ANTIMICROBIAL RESISTANCE Keryn J Christiansen, John D Turnidge, Jan M Bell, Narelle

More information

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S

Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S CRE Enterobacteriaceae (Gram Negative Bacilli) Citrobacter species Escherichia coli***

More information

Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities

Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Introduction As the problem of antibiotic resistance continues to worsen in all healthcare setting, we

More information

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Unusual Increase of Vancomycin-resistant Enterococcus faecium but not Enterococcus faecalis at a University Hospital in Taiwan

Unusual Increase of Vancomycin-resistant Enterococcus faecium but not Enterococcus faecalis at a University Hospital in Taiwan Original Article 493 Unusual Increase of Vancomycin-resistant Enterococcus faecium but not Enterococcus faecalis at a University Hospital in Taiwan Ping-Cherng Chiang 1,3, MD; Tsu-Lan Wu 2, MS; Jiunn-Yih

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,

More information

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018 Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?

More information

Effect of Antibiotic Treatment on Establishment and Elimination of Intestinal Colonization by KPC-Producing Klebsiella pneumoniae in Mice

Effect of Antibiotic Treatment on Establishment and Elimination of Intestinal Colonization by KPC-Producing Klebsiella pneumoniae in Mice ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2011, p. 2585 2589 Vol. 55, No. 6 0066-4804/11/$12.00 doi:10.1128/aac.00891-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Effect

More information

JAC Enterococci with reduced susceptibility to vancomycin in New Zealand

JAC Enterococci with reduced susceptibility to vancomycin in New Zealand Journal of Antimicrobial Chemotherapy (2000) 46, 405 410 JAC Enterococci with reduced susceptibility to vancomycin in New Zealand Kere Kobayashi a, Min Rao a, Stefanie Keis a, Frederick A. Rainey b, John

More information

Konsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program

Konsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes

More information

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an

More information

Surgical prophylaxis for Gram +ve & Gram ve infection

Surgical prophylaxis for Gram +ve & Gram ve infection Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance

More information

WHO Surgical Site Infection Prevention Guidelines. Web Appendix 4

WHO Surgical Site Infection Prevention Guidelines. Web Appendix 4 WHO Surgical Site Infection Prevention Guidelines Web Appendix 4 Summary of a systematic review on screening for extended spectrum betalactamase and the impact on surgical antibiotic prophylaxis 1. Introduction

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's

More information

Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA

Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA Long Term Care Facilities: Spectrum low acuity assisted living mobile independent Not LTAC high acuity complete functional disability dialysis

More information

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

Received 15 October 2006/Returned for modification 20 December 2006/Accepted 15 February 2007

Received 15 October 2006/Returned for modification 20 December 2006/Accepted 15 February 2007 JOURNAL OF CLINICAL MICROBIOLOGY, May 2007, p. 1556 1560 Vol. 45, No. 5 0095-1137/07/$08.00 0 doi:10.1128/jcm.02116-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Evaluation

More information

Please distribute a copy of this information to each provider in your organization.

Please distribute a copy of this information to each provider in your organization. HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to

More information

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov

More information

Who should read this document 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version 3. Policy/Procedure/Guideline 3

Who should read this document 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version 3. Policy/Procedure/Guideline 3 Antibiotic Prophylaxis in Cranial Neurosurgery Antibiotic Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary

More information

North West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families

North West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families Document Title and Reference : Guideline for the management of multi-drug resistant organisms (MDRO) Main Author (s) Simon Power Ratified by: GM NSG Date Ratified: February 2012 Review Date: March 2017

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control

More information

TREAT Steward. Antimicrobial Stewardship software with personalized decision support

TREAT Steward. Antimicrobial Stewardship software with personalized decision support TREAT Steward TM Antimicrobial Stewardship software with personalized decision support ANTIMICROBIAL STEWARDSHIP - Interdisciplinary actions to improve patient care Quality Assurance The aim of antimicrobial

More information

ORIGINAL ARTICLE /j x. and 2 Department of Infectious Diseases, Westmead Hospital, Westmead, New South Wales, Australia

ORIGINAL ARTICLE /j x. and 2 Department of Infectious Diseases, Westmead Hospital, Westmead, New South Wales, Australia ORIGINAL ARTICLE 10.1111/j.1469-0691.2008.02052.x Difficulties in detection and identification of Enterococcus faecium with low-level inducible resistance to vancomycin, during a hospital outbreak S. Pendle

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

Screening programmes for Hospital Acquired Infections

Screening programmes for Hospital Acquired Infections Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,

More information